This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eli Lilly & Company
Drug Names(s): raloxifene hydrochloride, Optruma
Description: Evista is a Selective Estrogen Receptor Modulator (SERM) that belongs to the benzothiophene class of compounds. A loss of estrogen is strongly associated with bone loss. Evista binds to and activates the estrogen receptor which leads to a reduction in bone resorption and bone turnover.
Revenue splits for this drug are BioMedTracker estimates.
**Since 2011, Daiichi has not reported revenues for Evista in Europe.
Evista was developed by Eli Lilly. In December 1995, under the terms of an agreement, Lilly will receive signing and milestone payments from Chugai, and both parties will share the costs and resources to develop raloxifene for the treatment of osteoporosis from 1996 through regulatory submission in Japan. Once approved, both companies will share responsibility for all marketing activities and, in exchange for its support, Chugai will earn performance-related payments based on total net sales of raloxifene in Japan. In November 2012, Eli Lilly Japan and Chugai agreed to terminate the agreement regarding co-marketing of EVISTA tablet 60mg as of December 31, 2012. Lilly will be solely responsible for the distribution and commercialization of EVISTA in Japan from January 2013.
In May 2005, the U.S. District Court of Massachusetts in...See full deal structure in Biomedtracker
Partners: ARIAD Pharmaceuticals, Inc. Daiichi Sankyo Co., Ltd. Takeda Pharmaceutical Company Ltd
Pink Sheet In Brief: Lilly Evista
Additional information available to subscribers only: